Drug news
Albireo licences Asian rights for Elobixibat to Ajimoto
Albireo Pharma licences Ajimoto rights to elobixibat in Japan, South Korea, Thailand, Indonesia, Vietnam and Taiwan.Elobixibat is a first-in-class investigational drug in development for chronic constipation and irritable bowel syndrome with constipation .Phase II trials have been promising.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.